Peanuts for Cardiometabolic, Brain, and Intestinal Health

ConditionsPrediabetes Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)Cognition Microvascular Function Gut Microbiota Endothelial Function (Reactive Hyperemia)Arterial Stiffness, Blood Pressure Adult

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age20-59

SponsorGeorgia State University

About this trial

The overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.

Eligibility criteria

Qualifiers

men and women

20-59 years of age

BMI: 24.5 - 35.5 kg/m²

Prediabetes (fasting blood glucose levels 100-125 mg/dL and/or HbA1c between 5.7-6.4%)

Disqualifiers

Allergies to peanuts and peanut products

Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs

Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury

Smoking

Trial design

Treatments tested in this trial

Peanuts

Treatment groups

72 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Georgia State University

Lead sponsor

United States Department of Agriculture (USDA)

Collaborator

The Peanut Institute

Collaborator

Source ClinicalTrials.gov